Merck Seeks To Enter RSV Market With Immunization For Infants

Pharmaceutical company Merck is seeking to enter the market for respiratory syncytial virus (RSV) vaccines, announcing Tuesday (July 23) it has received positive topline results from a clinical trial evaluating its prophylactic monoclonal antibody for infants, known as clesrovimab. Merck said clesrovimab met its primary safety and efficacy endpoints, including reducing instances of respiratory virus infections caused by RSV through day 150 after vaccination. The company intends to present detailed findings at an upcoming scientific conference and submit the data...